Reunion Neuroscience Inc. announced the appointment of Greg Mayes as president. As the company's new president Mr. Mayes' initial focus will be on the successful completion of the company's Phase 1 clinical trial with its lead asset, RE-104, a novel serotonergic psychedelic, which commenced in August 2022, and the planned launch of its Phase 2 study in postpartum depression, which is expected to commence in 2023. Mr. Mayes will also drive and accelerate Reunion's preclinical RE-200 research, which is focused on the discovery of selective and specific serotonergic psychedelics.

Prior to joining the company, Mr. Mayes served in multiple C-Suite leadership roles at early-stage biotech and pharmaceutical companies, where he was integral in raising nearly half a billion dollars in investment capital and overseeing the successful completion of multiple early-phase FDA trials. As President and CEO of Antios Therapeutics, a clinical-stage biopharmaceutical company, Mayes led a $100+ million Series B financing with top healthcare investors in 2021. Prior to Antios, and inspired by his son's epilepsy diagnosis, Mr. Mayes founded Engage Therapeutics, where he successfully raised $40 million in a Series A financing round led by TPG.

He served as the Engage Therapeutics President and CEO from 2017 until 2020 when the company was acquired by UCB Pharma for $270 million, following a positive, randomized Phase 2b clinical trial evaluating its lead product candidate, a REST (Rapid Epileptic Seizure Termination) treatment. Additionally, prior to founding Engage Therapeutics, Mr. Mayes played an integral role in the growth of Advaxis Immunotherapies (ADXS), a biotech company developing immuno-oncology therapies for patients with hard-to-treat cancers through its bacterial vector system. As Chief Operating Officer, he was instrumental in helping to secure more than $200 million in funding and in identifying and negotiating major pharmaceutical partnerships.

It is anticipated that Mr. Mayes will be appointed to the Reunion Board of Directors to replace Ronan Levy, Reunion co-founder and current Chairman and CEO of Field Trip Health & Wellness Ltd., who will step down from Reunion's Board in October 2022.